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Abstract 
Aims: Amyotrophic lateral sclerosis / motor neurone disease (ALS/MND) is characterised by 
the presence of inclusions containing TDP-43 within motor neurones. In rare cases, 
ALS/MND may be associated with inclusions containing other proteins, such as fused in 
sarcoma (FUS), whilst motor system pathology may rarely be a feature of other 
neurodegenerative disorders. We here have investigated the association of FUS and tau 
pathology. 
Methods: We report a case with an ALS/MND-plus clinical syndrome which pathologically 
demonstrated both FUS pathology and an atypical tauopathy.  
Results: Clinical motor involvement was predominantly upper motor neurone, and was 
accompanied by extrapyramidal features and sensory involvement, but with only minimal 
cognitive impairment. The presentation was sporadic and gene mutation screening was 
negative. Post-mortem study demonstrated inclusions positive for FUS, including basophilic 
inclusion bodies. This was associated with 4R-tauopathy, largely as non-fibrillary diffuse 
phospho-tau in neurones, with granulovacuolar degeneration in a more restricted 
distribution. Double-staining revealed that neurones contained both types of protein 
pathology.  
Conclusion: FUS-positive basophilic inclusion body disease is a rare cause of ALS/MND, 
but in this case was associated with an unusual atypical tauopathy. The coexistence of two 
such rare neuropathologies raises the question of a pathogenic interaction.  
 
Key words: motor neurone disease, amyotrophic lateral sclerosis, fused in sarcoma, 
basophilic inclusion body disease, atypical tauopathy. 
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Introduction 
Amyotrophic lateral sclerosis / motor neurone disease (ALS/MND) is characterised, in most 
cases, by neuronal protein aggregates that contain phosphorylated TDP-43, associated with 
nuclear mislocalisation. The ALS variant of motor neurone disease is characterised by upper 
and lower motor neurone involvement. Extramotor pathology can be seen, particularly in 
frontal cortex and hippocampus, and TDP-43 pathology may be seen in glia as well as 
neurones [1]. Motor system degeneration may however, rarely be associated with other 
neurodegenerative disorders and protein deposition.  
Fused in sarcoma (FUS), also known as translated in sarcoma, may form inclusions in rare 
cases of familial ALS/MND type 6 [2, 3]. These inclusions do not contain TDP-43 or tau. FUS 
inclusions also characterise a subset of frontotemporal lobar degenerations (FTLD-FUS), 
which includes three entities; atypical FTLD with ubiquitinated inclusions, basophilic 
inclusion body disease (BIBD) and neuronal intermediate filament inclusion disease (NIFID) 
[4]. In contrast to ALS/MND-FUS, these FUS-associated frontotemporal dementias are not 
usually associated with FUS mutation, and the inclusions contain other proteins (e.g. 
transportin-DQGLQWKHFDVHRI1,),'Į-internexin). Given these differences between 
ALS/MND-FUS and FTLD-FUS, it is unclear whether they are part of a disease spectrum. 
Tau pathology has also been described in association with ALS/MND, although tau 
deposition is not a feature of the typical inclusions of ALS/MND-TDP.  Abnormal neuronal 
and glial tau phosphorylation has been suggested in the ALS/MND spectrum [5, 6] but, other 
studies have found that this is mostly low-%UDDNVWDJH$O]KHLPHU¶VW\SHSDWKRORJ\DQGKDYH
not confirmed glial tau pathology [7]. A lack of predilection for enhanced tauopathy in FTLD-
TDP, and of TDP-43 in FTLD-tau, suggests a lack of direct interaction [8].  
Motor cortical degeneration, with upper motor neurone signs, may rarely be a feature of 
primary and secondary tauopathies, although usually in the context of other more typical 
dominant signs. Both progressive supranuclear palsy and corticobasal degeneration may 
demonstrate motor cortex involvement and corticospinal tract degeneration [9, 10], whilst 
globular glial tauopathy, also a 4-repeat tauopathy, may present with motor neurone disease 
plus dementia, and associated with atrophy of the precentral gyrus [11, 12]$O]KHLPHU¶V
disease may also rarely demonstrate corticospinal tract involvement, particularly familial 
cases associated with presenilin-1 mutations, and is DVVRFLDWHGZLWK$ȕGHSRVLWHGDVFRWWRn 
wool plaques [13].  
Here we report an unusual sporadic case with an ALS/MND-plus clinical phenotype and with 
complex neurodegeneration, combining both FUS pathology and an atypical tauopathy. This 
co-occurrence of two unusual pathologies, with dual pathology in the same neurones, would 
seem an unlikely coincidence and suggests that, in some FUS cases and in selected 
neuroanatomical areas, there may be a pathogenic interaction between FUS and tau. 
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Clinical Features 
A 43 year old man presented with a 12 month history of dexterity problems predominantly 
affecting his right hand, associated with mild weakness and episodic paraesthesia in the 
right hand and forearm, with mildly reduced sensation+LVPRWKHUGHYHORSHG$O]KHLPHU¶V
disease at age 75 years but there was no other family history of neurological disease.   Over 
the following 2-years he had increasing difficulty with the use of his hands, and reported 
wasting of the right, first dorsal interosseous muscle. Electrophysiology, MRI scan of the 
brain and cervical spine with gadolinium, lumbar puncture, anti-neuronal antibodies and EEG 
remained normal. However, a SPECT (single-photon emission computerized tomography) 
scan demonstrated bilateral multifocal hypoperfusion, both cortical and deep, and a DAT 
(dopamine transporters) scan showed decreased uptake. The patient was given a trial of 
baclofen and then levodopa with no discernible benefit. By two years after initial 
presentation, the right upper limb weakness had progressed, and walking balance was 
impaired, causing stumbling and falls. He reported widespread muscle twitching, and 
episodic, short-lived sharp pains in limbs. Although he reported some cognitive slowing, on 
bedside examination cognitive function was preserved, speech was clear, and he had a 
normal gait. He had severe weakness of the right upper limb with milder changes affecting 
the left upper limb. The lower limbs were normal in tone and power. Reflexes were brisk 
throughout, but the plantar responses were flexor.  No definite sensory or cerebellar signs 
were elicited. EMG now showed chronic denervation and ongoing reinnervation in 3 regions, 
with normal nerve conduction studies. However no active denervation was seen.  
The following year the patient developed dramatic mirror movements. A trial of ropinirole 
gave no discernible benefit.  Progressive deterioration in the strength of upper and lower 
limbs continued, spasticity became a problem and his speech became dysarthric. He also 
developed bradykinesia, loss of coordination and impaired proprioception, and he described 
himself at times as unaware of his body position. He had difficulty with sequencing of actions 
and became emotionally labile. He also developed urinary frequency and urgency. Non-
invasive ventilation was introduced due to a reduction in forced vital capacity and 
symptomatic hypercapnia. A re-trial of dopaminergic medication was unsuccessful. An FDG-
PET scan was performed (approximately 4yrs after presentation) DQGDµVWULSHVLJQ¶RI
hypometabolic activity in the primary motor cortices (PMC) was seen. Progressive weakness 
in all muscle groups, including the bulbar muscles, continued, necessitating a gastrostomy 
tube insertion, and the patient died 11 years after symptom onset. 
Genotyping was performed by Sheffield Diagnostic Genetics Service for ALS and dementia 
related gene panels (Supplementary table 1). The genes screened were all negative for 
mutation, including FUS, MAPT, and C9ORF72. 
 
Neuropathology 
Consent was obtained for a post mortem examination limited to brain and spinal cord, with 
donation of tissue to the Sheffield Brain Bank. Following transfer to our institution, the brain 
and spinal cord were removed with a post mortem interval (PMI) of approximately 96hr. A 
portion of cerebellum was flash frozen in liquid nitrogen for storage at -80 °C. The brain and 
cord were fixed in formalin prior to dissection; hemi-brain slices were not flash frozen 
according to the usual brain bank protocols because of the extended PMI. The brain, 
weighing 1455g, showed moderate atrophy of the motor cortex, with mild atrophy of primary 
sensory cortex and superior parietal lobe (Figure 1A,B). The corpus callosum was thinned in 
the mid-cerebrum and the medullary pyramids were atrophic and grey.   
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Microscopical examination of haematoxylin and eosin stained sections revealed spongiosis 
of the motor cortex with pallor of underlying white matter (Figure 1C-D). Many pyramidal 
neurones contained ovoid, circumscribed, basophilic inclusion bodies, in some cases 
associated with vacuoles containing dot-like profiles suggestive of granulovacuolar 
degeneration (GVD) (Figure 1E-F). The basophilic  inclusions immunolabelled with 
antibodies to FUS (Novus Biologicals polyclonal rabbit antibody NB100-2599, 1:100, 
pressure cooker antigen retrieval pH9 Menarini super buffer), which also showed neuronal 
cytoplasmic labelling, and ring-like fibrillary structures (Figure 2A,B).  
Inclusions labelled with immunohistochemistry to P62 (BD Bioscience monoclonal 1:400 
high pH retrieval Dako autostainer), which also labelled circumscribed inclusions in 
pyramidal neurones and ring-like reactivity in neurons in layer 2 (Figure 2C), corresponding 
to areas with frequent FUS positivity. The inclusions did not show argyrophilia with the 
Gallyas method (Figure 2D). AT8 immunostaining (Thermo Scientific monoclonal 1:800, no 
antigen retrieval Dako autostainer) identified diffuse granular positivity in pyramidal neurones 
and labelled granulovacuolar degeneration and numerous neuropil threads. AT8+ neurons 
were most conspicuous in the deeper cortex. Neurofibrillary tangles were not observed and 
AT8 did not label the basophilic inclusions. No tau-positive glial inclusions were seen.  
Immunohistochemistry to 4R-tau (Millipore monoclonal antibody 05-804 clone 1E1/A6, 
1:3000 with pressure cooker antigen retrieval) labelled tau in some of the neurons and 
neuropil threads, whilst immunohistochemistry to 3R tau (Millipore monoclonal antibody 05-
803, clone 8E61C11, KMnO4 bleach followed by incubation 1:800 4C for 2 days with 
pressure cooker antigen retrieval) was negative (Figure 2E-I). The distribution of staining is 
shown in Supplementary table 2. Notably AT8 immunoreactivity showed a more restricted 
neuroanatomical distribution than p62 or FUS.  
Double immunostaining for FUS and AT8 was performed on motor cortex. Following 
pressure cooker antigen retrieval at pH6, FUS was stained first using a polymer kit at 1:100 
with DAB (giving a brown reaction product), followed by AT8 at 1:200 with a standard ABC 
kit with vector VIP (giving a blue/purple reaction product). This demonstrated co-existence of 
these protein pathologies in some neurons (Figure 3A-B, Suppl Figure 1). Small samples (2-
3mm) of formalin-fixed tissue from motor cortex were sub-dissected, subsequently fixed in 
glutaraldehyde and processed for electron microscopy. Ultrastructural examination revealed 
circumscribed inclusions, which contained polyribosomes arranged in an apparent linear-
helical pattern (Figure 3C-D). Lipofuscin and autophagic vacuoles were also noted. 
However, no filamentous structures were identified in the inclusions and no limiting 
membrane was detected, although state of preservation linked to the PMI and suboptimal 
fixation (for ultrastructure) may have limited detection of some structures. 
The medullary pyramids were atrophic and there was loss of lower motor neurones from the 
hypoglossal nucleus and anterior horns of the spinal cord, especially at cervical levels 
(Figure 4A-D). Neither Bunina bodies nor hyaline conglomerate inclusions were identified. 
CD68, an indirect marker of long tract degeneration [14], was upregulated in the lateral 
corticospinal tracts of the cord. FUS/p62 positive inclusions were identified in lower motor 
neurones. There were no TDP-43-positve incluVLRQVQRUPLVORFDOLVDWLRQDQGQRĮ-synuclein 
inclusions in either upper or lower motor neurones.  No amyloid-ȕSDWKRORJ\ZDVGHWHFWHG 
Extramotor pathology was also present (Figure 4E-I). Milder pathology, with an occasional 
balloon neuron, was observed in primary sensory cortex. Prefrontal association cortex 
(BA8/9) showed only focal layer 2 spongiosis. The substantia nigra revealed moderate cell 
loss with pigment incontinence. Immunohistochemistry revealed inclusions in primary 
sensory cortex, with only occasional inclusions in prefrontal cortex. Sparse AT8+ tangles in 
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entorhinal cortex probably represented age-associated Braak stage I neurofibrillary 
pathology. However, many GVD-like inclusions were observed in CA1 pyramidal layer 
neurones. Inclusions were observed in caudate and putamen. P62/FUS+ inclusions were 
present in the dentate nucleus of the cerebellum; these were AT8-negative and there was no 
grumose degeneration. White matter did not show inclusions and no glial tau pathology was 
identified in either grey or white matter structures.  
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Discussion 
We report a complex case of neurodegenerative disease with combined protein pathology, 
presenting primarily with a sporadic ALS/MND phenotype, with pathological involvement of 
motor cortex and lower motor neurones, but with extramotor pathology, most notably in 
sensory cortex. The case was characterised by both FUS pathology with basophilic inclusion 
body formation, combined with an atypical non-fibrillar 4R tauopathy, and an absence of 
pathogenic mutations.  
There was ante-mortem diagnostic uncertainty due to clinical features not easily defined by 
one neurodegenerative disorder, and investigations demonstrating cortical and subcortical 
involvement. The clinical differential diagnosis was of atypical primary lateral sclerosis (PLS) 
and corticobasal degeneration (CBD). PLS is a motor neurone disease with only upper 
motor neurone (UMN) degeneration and corticobasal degeneration is an extrapyramidal 
motor disorder without significant weakness. This patient had UMN-pattern weakness with 
only a hint of muscle wasting to suggest LMN involvement and EMG showed evidence of 
chronic denervation without active denervation and without the spontaneous muscle activity 
seen with LMN loss. PET scan showed a primary motor cortex hypometabolic stripe that can 
be seen in PLS, but not exclusively so [15, 16]. He had mild sequencing problems in addition 
to bradykinesia, reduced coordination, mirror movements and rigidity. Extra-pyramidal signs 
are recognised in motor neuron disease and it can be difficult to distinguish between UMN 
spasticity and rigidity of extra-pyramidal origin. The patient was prescribed baclofen but 
without complete relief of symptoms. He had an abnormal SPECT and DAT scan but without 
response to dopaminergic therapy. Extramotor involvement was present with paraesthesia 
and reduced proprioception. He had a subjective mild cognitive deficit but certainly not overt 
fronto-temporal dementia (FTD) that can be seen with either ALS/MND or tauopathy, nor did 
he have the cognitive problems seen with CBD.  
FUS was present in basophilic, and other neuronal inclusions, suggestive of BIBD.  
ALS/MND-FUS is usually associated with FUS mutation [2, 3] and, although UMN features 
are present, this disorder typically has a LMN pattern [17]. Our case, in contrast, 
demonstrated severe involvement of the motor cortex with UMN weakness, whilst CD68 
staining demonstrated evidence of corticospinal tract degeneration. Furthermore, our case 
appeared to be sporadic and extensive genetic testing revealed no evidence of a mutation.   
Electron microscopy demonstrated that the inclusions contain organellar structures 
containing polyribosomes. Polyribosomes associated with a central filament are described in 
the BIBD inclusions. This appearance is consistent with that, although a central filament was 
not conspicuous. These structures also resemble  helical polyribosomes, an unusual 
ribosomal formation described in various cell types, including intestinal cells of rat fetus, 
muscle cells of Rana pipiens embryo, follicular cells and oocytes of rat ovary, various cells in 
culture, certain non-mammalian cell types [18] and in mammalian cells may be associated 
with decreased translation [19, 20].  
In addition, there was an unusual atypical tauopathy, characterised by diffuse deposits, 
neuropil threads and GVD. Although present in brain areas affected by the p62 and FUS 
inclusions, it had a restricted distribution to motor cortex and hippocampus, the latter 
containing pyramidal neurons in which GVD can typically form.  Ultrastructural examination 
demonstrated that the neuronal inclusions do not contain fibrillary structures as may be seen 
in other tauopathies, including PSP and CBD [21]. Thus both light and electron microscopic 
studies suggest that the tau is non-fibrillar.  Glial tau was not a conspicuous feature. 
Immunohistochemistry suggests that this belongs to the 4R-tauopathy group, although we 
were not able to confirm this with western blotting as suitable frozen tissue was not 
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available. TDP-43 pathology was not present as a co-pathology. This tauopathy 
demonstrates unique features that do not fit with existing diagnostic categories. Corticospinal 
degeneration may be a feature of several tauopathies, although it is seldom a dominant 
feature. CBD and PSP may occasionally demonstrate corticospinal tract degeneration and 
long tract signs reminiscent of primary lateral sclerosis [9, 10]. This case also had some 
subtle extrapyramidal features clinically and degeneration of the substantia nigra 
pathologically. Given the pattern of atrophy, with superior parietal and sensory cortex 
involvement, as well as motor involvement, a particular nosological question is whether the 
tau pathology falls within the spectrum of CBD. Immunohistochemical positivity for 4R tau 
supports a relationship. However, although occasional balloon neurons were seen, other 
features of the pathology of this case were not typical of those described for CBD, PSP or 
other reported tauopathies [22]. These included the presence of conspicuous GVD. 
Grumose degeneration of the cerebellar dentate nucleus and neurofibrillary tangles were not 
features and neither astrocytic plaques nor oligodendroglial tau inclusions were seen. 
Globular glial tauopathy is an emerging 4-repeat tauopathy, distinguished by characteristic 
globular oligodendroglial inclusions, that can present with an ALS/MND phenotype, [11]. 
Globular glial 4-repeat tau, associated with TDP43 pathology has been reported in 
association with an ALS/MND and FTD phenotype [23]. Our case lacked the glial tau 
pathology characteristic of these disorders.  Fronto-temporal lobar degeneration with tau 
positive inclusions (FTLD-tau) may also rarely have pyramidal signs particularly when 
associated with particular tau-gene (MAPT) mutations, such as K317M [24]. However, only 
sparse tau pathology was observed in frontal cortex in this case, which did not have an 
FTLD pathological phenotype, nor an FTD clinical phenotype, and there was no MAPT 
mutation.  
BIBD is a rare disease and FUS inclusions are negative for tau. FTLD-FUS of the NIFID 
subtype has been reported in association with a progressive supranuclear palsy pattern of 
tau [25], but this does not resemble the tauopathy of this case. The coexistence of BIBD with 
an atypical tauopathy involving similar brain areas suggests a pathogenic relationship, and 
double staining showed co-pathology in pyramidal neurons. A notable feature of this case is 
the presence of GVD. Motor cortex is an unusual site for this pathology, although pyramidal 
layer of hippocampus is a typical site, These tau-containing structures may be related to 
macroautophagy [26], and disturbance of protein homeostasis and autophagy may be a 
common feature of neurodegenerative disorders.  ALS/MND-associated mutant FUS has 
been shown to impair autophagy [27]. Furthermore, tau mRNA is a splicing target of FUS 
[28]. These suggest mechanisms by which FUS pathology may be a driver of tau pathology, 
so that the presence of these two unusual pathologies may be pathogenically linked in this 
case. However, the tau pathology here has a more restricted distribution than FUS, so that 
additional cellular factors may determine whether the pathologies are co-expressed. Whilst 
these findings may suggest a pathogenic interaction, they do not provide proof, and further 
cell biological studies and detailed studies of tau mRNA and protein may be warranted in 
FUS-pathology cases, even those without overt phospho-tau deposition. 
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Figure Legends 
Figure 1: Motor Cortex Pathology. A. Following stripping of the leptomeninges, atrophy is 
noted in the precentral gyrus (1). Mild atrophy is also apparent in the post-central gyrus (2) 
and superior parietal lobule (3). B. Coronal slice at the level of the lateral geniculate nuclei, 
showing bilateral atrophy of motor cortex (arrows). C. Low power view of motor cortex 
showing atrophy and spongiosis. D. Immunohistochemistry for GFAP demonstrates gliosis. 
E. Pyramidal neurone in motor cortex showing granulovacuolar degeneration (arrow). F. 
Basophilic inclusion within a neurone (arrow). Magnification bars: C 1000ȝm, D 500ȝm, E, F 
10ȝm 
Figure 2: Immunohistochemical Findings in Motor Cortex. A, B. FUS labels compact 
neuronal inclusions in pyramidal neurones (arrows). A ring-like inclusion is also seen in B 
(open arrow). Note variable nuclear staining. C. Labelling of inclusions in layer 2 for p62. D. 
Gallyas preparation showing lack of argyrophilia of a compact inclusion (arrow). E. 
Immunohistochemistry with the AT8 antibody to phospho-tau demonstrating extensive 
deposition in motor cortex. F. AT8 labels diffuse tau in neurones (arrows) and numerous 
neuropil threads. G. Immunohistochemistry to 3R tau does not label inclusions. H. 
Immunohistochemistry to 4R tau labels some neurones and (I.) neuropil threads. 
Magnification bars: A 1000ȝm, B, E 500ȝm, C, D, F 10ȝm, G 100ȝm, H,I 50ȝm 
Figure 3 Detail of inclusions in motor cortex. A-B Double immunostaining for FUS 
(brown) and AT8 (purple). Neurites are AT8+, compact inclusions contain FUS. Fine 
granular positivity for AT8 and GVD are seen in neurones that also contain FUS (arrows), 
but some FUS positive neurones do not contain tau pathology (open arrow, B). Inset (B) 
shows an enlarged image of a neurone with more diffuse tau positive (purple) on a diffuse 
brown FUS+ background. 0DJEDUVȝP': Ultrastructural examination reveals 
circumscribed cytoplasmic inclusions. Mag bar 1000nm. E. Higher power view reveals 
helical polyribosome structures but no filamentous structures. Mag bar 200nm.  
Figure 4: Lower motor neurone and extramotor pathology. A. Low power view of 
cervical cord showing neuronal loss from the anterior horns. B. CD68 immunohistochemistry 
revealing microglial up-regulation in the lateral corticospinal tract of the cord. C. FUS+ve 
inclusions in anterior horn motor neurones (arrow). D. TDP-43 immunohistochemistry 
reveals no inclusions and normal nuclear localisation. E. Spongiosis of primary sensory 
cortex. F. Neuronal loss and pigmentary incontinence in the substantia nigra. G. AT8+ 
inclusions in the CA1 region of the hippocampus. H. Basophilic inclusion in dentate neurone 
of the cerebellum (arrow). I. Inclusions in cerebellar dentate, labelled with 
immunohistochemistry to FUS. Magnification bars: A 500ȝm, B, DF,  100ȝm, C,G, I 50ȝm, H 
10ȝm. 
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